Lingli Zhang
机构：Central University of Finance and Economics, China Pharmaceutical University · ORCID：0000-0001-7987-0217
发表论文 15 篇 · 总被引 66 次 · h-index 5
代表论文
- Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China (2024 · International Journal of Clinical Pharmacy · 被引 16)
- Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment (2024 · Health Expectations · 被引 15)
- Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis (2025 · Annals of Medicine · 被引 12)
- Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe (2024 · International Journal of Clinical Pharmacy · 被引 8)
- Public Preference and Priorities for Including Vaccines in China’s National Immunization Program: Discrete Choice Experiment (2024 · JMIR Public Health and Surveillance · 被引 7)
- Quantifying stakeholders’ preference for implantable medical devices in China: a discrete choice experiment (2024 · International Journal of Technology Assessment in Health Care · 被引 3)